OCS Liver adoption surged, with share of total U.S. liver transplants rising from 26% in 2024 to 36% in 2025. Operating margin expanded from 8.5% in 2024 to 18% in 2025, though guidance for 2026 ...
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today ...
Moby Operational Performance and Strategic Positioning. Achieved record performance in Q4 2025, validating management's vie ...
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today ...
ANDOVER, Mass., July 16, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...
SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- A class-action lawsuit has been filed against the medical technology company, which specializes in organ transplant therapy, alleging that the company ...
ANDOVER, Mass., Feb. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant ...
or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit ...
Q4 2025 Earnings Call February 24, 2026 4:30 PM ESTCompany ParticipantsWaleed Hassanein - Founder, President, CEO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results